Home » Topics » BioWorld Science

BioWorld Science
RSS

First-in-human study of PLN-1474 for the treatment of liver fibrosis

March 24, 2020

FDA approves phase III study of Actemra in patients with severe COVID-19 pneumonia

March 24, 2020

European Commission approves intravenous formulation of Akynzeo

March 24, 2020

AnHeart receives clinical trial authorization for taletrectinib in China

March 24, 2020

Recruiting NK cells to the antitumor battle

March 24, 2020

BET on BD1 for cancer, BD2 for inflammation

March 24, 2020

Sorrento develops Covidtrap protein for potential prevention and treatment COVID-19

March 24, 2020

Harpoon initiates phase I/II study of HPN-217 in relapsed or refractory multiple myeloma

March 23, 2020

Precision Biosciences begins phase I/IIa study of PBCAR-20-A for relapsed/refractory NHL and CLL/SLL

March 23, 2020

U.S. complete response letter issued for empagliflozin for type 1 diabetes

March 23, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...